Possibilities of using of lornoxicam in the treatment of pain in rheumatic diseases
https://doi.org/10.14412/1996-7012-2025-5-127-132
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) occupy one of the central positions in the multimodal control of acute and chronic musculoskeletal pain and have broad indications, including rheumatic diseases. Lornoxicam, an oxicam-class NSAID, is a balanced cyclooxygenase (COX)- 1/COX-2 inhibitor characterized by rapid onset of its effect, fast elimination, and a short half-life, which reduces the risk of its accumulation and provides good tolerability. Therapeutic equivalence has been demonstrated among the three lornoxicam formulations (Xefocam tablets, Xefocam injection, and Xefocam Rapid), obviating the need for dose adjustment when switching from parenteral to oral administration.
Keywords
Supporting agencies: The article is sponsored by NIZHPHARM.
About the Authors
L. I. Alekseeva
V.A. Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Liudmila Ivanovna Alekseeva
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
T. A. Raskina
Kemerovo State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
22A, Voroshilova Street, Kemerovo 650056
E. A. Taskina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Yakhno NN, editor. Pain. Practical guide. Moscow: MEDpress-inform; 2022.
2. Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of musculoskeletal pain treatment: interdisciplinary consensus. Nauchno-prakticheskaya revmatologiya. 2016;54(3):247-265. (In Russ.).
3. Khalil NA, Ahmed EM, Tharwat T, Mahmoud Z. NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead. RSC Adv. 2024 Sep25;14(42): 30647-30661. doi: 10.1039/d4ra04686b.
4. Pota V, Coppolino F, Barbarisi A, et al. Pain in Intensive Care: A Narrative Review. Pain Ther. 2022 Jun;11(2):359-367. doi: 10.1007/s40122-022-00366-0.
5. Yang Z, Mathieson S, Kobayashi S, et al. Prevalence of Nonsteroidal Antiinflammatory Drugs Prescribed for Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken). 2023 Nov;75(11):2345-2358. doi: 10.1002/acr.25157.
6. Ju Z, Li M, Xu J, et al. Recent development on COX-2 inhibitors as promising antiinflammatory agents: The past 10 years. Acta Pharm Sin B. 2022 Jun;12(6):2790-2807. doi: 10.1016/j.apsb.2022.01.002.
7. Karateev AE, Aleinikova TL. Eicosanoids and inflammation. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4): 73-86. (In Russ.). doi: 10.14412/1996-7012-2016-4-73-86.
8. Westman M, Korotkova M, af Klint E, et al. Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum. 2004 Jun;50(6):1774-80. doi: 10.1002/art.20286.
9. Korotkova M, Jakobsson PJ. Microsomal prostaglandin e synthase-1 in rheumatic diseases. Front Pharmacol. 2011 Jan 20;1:146. doi: 10.3389/fphar.2010.00146
10. Korotkova M, Westman M, Gheorghe KR, et al. Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway. Arthritis Rheum. 2005 Nov;52(11):3439-47. doi: 10.1002/art.21390.
11. Kojima F, Naraba H, Miyamoto S, et al. Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther. 2004;6(4): R355-65. doi: 10.1186/ar1195.
12. Gheorghe KR, Thurlings RM, Westman M, et al. Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression. PLoS One. 2011 Jan 27; 6(1):e16378. doi: 10.1371/journal.pone.0016378.
13. Karateev AE, Lila AM, Mazurov VI, et al. Expert consensus 2024: rational use of nonsteroidal anti-inflammatory drugs. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2025;19(S1):1-40. (In Russ.). doi: 10.14412/1996-7012-2025-1S-1-40
14. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. 2007 Sep;59(3):207-24. doi: 10.1124/pr.59.3.1.
15. Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective pros taglandin synthesis inhibitor. J Pharmacol Exp Ther. 1990 Jul;254(1):180-7.
16. Lombardino JG, Wiseman EH, McLamore WM. Synthesis and antiinflammatory activity of some 3-carboxamides of 2-alkyl-4-hydroxy 2H21,2-benzothiazine 1,1-dioxide. J Med Chem. 1971 Dec;14(12): 1171-5. doi: 10.1021/jm00294a008.
17. Berg J, Fellier H, Christoph T, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474.
18. Radhofer-Welte S, Dittrich P, Simin M, Branebjerg PE. Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers. Clin Drug Investig. 2008;28(6):345-51. doi: 10.2165/00044011-200828060-00002.
19. Ankier SI, Brimelow AE, Crome P, et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med J. 1988 Oct;64(756):752-4. doi: 10.1136/pgmj.64.756.752.
20. Berg J, Fellier H, Christoph T, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474.
21. Parada L, Marstein JP, Danilov A. Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain. Pain Manag. 2016 Oct;6(5):445-54. doi: 10.2217/pmt.16.7.
22. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28:354:i4857. doi: 10.1136/bmj.i4857.
23. Gorsky VA, Agapov MA, Khoreva MV, et al. The effect of lornoxicam on TLR2 and TLR4 messenger RNA expression and tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion in patients with systemic complications of acute pancreatitis. Pancreas. 2015 Jul;44(5):824-30. doi: 10.1097/MPA.0000000000000344.
24. Korotkova M, Jakobsson PJ. Characterization of Microsomal Prostaglandin E Synthase 1 Inhibitors. Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):64-9. doi: 10.1111/bcpt.12162.
25. Tamasi G, Bernini C, Corbini G, et al. Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium(III) oxicam complexes. In vivo evaluation of antiinflammatory and gastric damaging activities. J Inorg Biochem. 2014 May:134:25-35. doi: 10.1016/j.jinorgbio.2014.01.011.
26. Roy S, Banerjee R, Sarkar M. Direct binding of Cu(II)-com plexes of oxicam NSAIDs with DNA backbone. J Inorg Biochem. 2006 Aug;100(8):1320-31. doi: 10.1016/j.jinorgbio.2006.03.006.
27. Ritland SR, Gendler SJ. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis. 1999 Jan;20(1):51-8. doi: 10.1093/carcin/20.1.51.
28. Tasaki Y, Yamamoto J, Omura T, et al. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Aktmediated neuroprotection against 1-methyl- 4-phenyl pyridinium induced cytotoxicity. Eur J Pharmacol. 2012 Feb 15;676(1-3):57-63. doi: 10.1016/j.ejphar.2011.11.046.
29. Radhofer-Welte S, Dittrich P, Simin M, Branebjerg PE. Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular inj-ection: a randomized, open-label, crossover phase I study in healthy volunteers. Clin Drug Investig. 2008;28(6):345-51. doi: 10.2165/00044011-200828060-00002.
30. Clinical guidelines "Musculoskeletal (nonspecific) pain in the lower back", Ministry of Health of the Russian Federation, 2023.
31. Berry H, Bird HA, Black C, et al. A double-blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis. 1992 Feb; 51(2):238-42. doi: 0.1136/ard.51.2.238.
32. Kidd B, Frenzel W. A multicenter randomized double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol. 1996 Sep;23(9):1605-11.
33. Goregaonkar A, Mathiazhagan KJ, Shah RR, et al. Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study. Curr Ther Res Clin Exp. 2009 Feb;70(1):56-68. doi: 10.1016/j.curtheres.2009.02.006.
34. Rose P, Steinhauser C. Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. doi: 10.2165/00044011-200424040-00004.
35. Caruso I, Montrone F, Boari L, et al. Lornoxicam versus diclofenac in rheumatoid arthritis: a double-blind, multicenter study. Adv Ther. 1994;11(3):132-8.
36. Pleiner J, Nell G, Branebjerg PE, et al. Safety of lornoxicam: an interim meta-analysis of comparative clinical trials. Eur J Pain. 2009;13(Suppl 1):191. doi: 10.1016/S1090-3801(09)60662-5
37. Parada L, Marstein JP, Danilov A. Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain. Pain Manag. 2016 Oct;6(5):445-54. doi: 10.2217/pmt.16.7.
38. Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362.
39. Temirkulova ShA, Imasheva SS, Zhagmarova LK, Nasyrova NZ. Experience of using xefocam in the treatment of osteoarthritis in patients with arterial hypertension (AH). Nauchno-prakticheskaya revmatologiya. 2006;(2): 114. (In Russ.).
40. Vertkin AL, Naumov AV, Semenov PA, et al. Safety assessment of the use of lornoxicam and diclofenac sodium in general medical practice. Klinicheskaya Gerontologiya. 2009; 15(2):21-6. (In Russ.).
41. Khripunova IG, Khripunova AA, Mnatsakanyan SG. Xefocam for pain relief in patients with osteoarthritis (OA). Nauchno-prakticheskaya revmatologiya. 2006;(2):119. (In Russ.).
42. Koval'chuk VV, Efimov MA. Comparative characteristics of the efficacy and tolerability of short courses of therapy with various nonsteroidal anti-inflammatory drugs in the treatment of patients with dorsalgia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(1):55-58. (In Russ.).
Review
For citations:
Alekseeva LI, Raskina TA, Taskina EA, Lila AM. Possibilities of using of lornoxicam in the treatment of pain in rheumatic diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(5):127-132. (In Russ.) https://doi.org/10.14412/1996-7012-2025-5-127-132
Views:
18
Email this article 